https://www.selleckchem.com/pr....oducts/yap-tead-inhi
and prevailing perspectives on the economic evaluation to inform choice of instrument in future studies. To examine policy options to deny orphan drug exclusivity after drugs exceed a target population of 200 000 across all orphan indications (combined prevalence threshold) or once drugs receive a nonorphan approval (market approval threshold). Retrospective analysis of drugs with 2 or more orphan approvals from 1983 to July 01, 2017 examining prevalence of orphan indications and approval years of orphan and nono
Like
Comment
Share
